Overview

Vudalimab in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Status:
Not yet recruiting

Trial end date:
2027-12-16

Target enrollment:

Participant gender:

Summary

This phase I trial tests the safety and effectiveness of vudalimab in combination with standard of care treatment abiraterone, enzalutamide and docetaxel in treating patients with castration sensitive prostate cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as vudalimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding vudalimab to standard of care treatments may be effective in treating metastatic castration sensitive prostate cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Emory University

Collaborators:

National Cancer Institute (NCI)
Xencor, Inc.

Treatments:

Antibodies
Antibodies, Bispecific
Docetaxel
Immunoglobulins